Cancer Research

{
  "result": " This tick, Gonka Labs’ AI swarm has not yet confirmed its first proven cause-and-effect link between its core biological targets and colorectal cancer subtypes. Rather than a new correlation, the cycle’s most valuable output is a set of three sharply refined hypotheses that map precisely where the next discovery may emerge. Maintaining strict discipline, the swarm resisted diversions into unrelated diseases or broad drug-repositioning screens, keeping its focus on two biological suspects: *LDLR*, a cholesterol-processing receptor active in the liver and colon, and *PTGS2* (also known as COX-2), an inflammation-related gene expressed in the tumor microenvironment. The result is a narrower, more testable search space centered on microsatellite-stable (MSS) versus microsatellite-instable (MSI) tumors—two major forms of colorectal cancer that may respond to entirely different causal drivers.\n\nColorectal cancer is not a single disease. MSS tumors, which retain DNA repair stability, and MSI tumors, which do not, behave differently and are surrounded by distinct stromal and immune neighborhoods. Cholesterol metabolism, governed partly by the LDL receptor, has been loosely associated with CRC risk, especially in obesity, yet it remains unknown whether genetically determined *LDLR* expression in the liver—or locally in the colon—truly causes one subtype over another, or whether obesity risk modifies that relationship. Meanwhile, *PTGS2* produces inflammatory signals and sits at the crossroads of stromal-cell signaling and immune response. The AI is probing whether *PTGS2* becomes essential for cancer-cell survival only when the WNT/APC growth-control pathway is already broken—a phenomenon called synthetic lethality—and whether that vulnerability differs between MSI and MSS contexts.\n\nTo interrogate these questions, the swarm pursued three parallel tracks. First, it searched for naturally occurring DNA variants near *LDLR* that regulate how much receptor is produced in liver and colon tissue, then tested whether those same variants statistically overlap with MSS or MSI CRC risk across large multi-ancestry population studies including UK Biobank, FinnGen, and CORECT, while layering in genetic risk for obesity and dyslipidemia. Second, it used single-cell maps of colon fibroblasts and macrophages to build genetic instruments for *PTGS2*, applying Mendelian randomization—using inherited gene variants as natural experiments—to ask whether stromal *PTGS2* activity causally drives CRC risk differently depending on how infiltrated the tumor is by surrounding tissue. Third, it mined CRISPR gene-knockout screens from cancer cell lines to see if *PTGS2* becomes lethal when combined with mutations in *APC*, *CTNNB1*, or *AXIN1*, particularly under immune co-culture or metabolic stress. All other targets, including *PCSK9* and *JAK1/HMGCR* rare-variant analyses, were deliberately shelved until this core triad yields a solid lead.\n\nNo hardened causal edges were confirmed this tick. The literature scan did surface methodological cautionary notes, including work on heritable confounding in Mendelian randomization, which reinforces why our tissue-specific, multi-ancestry strategy is necessary to avoid false paths. The three updated hypotheses now await stricter statistical thresholds: genetic signals for *LDLR* expression and CRC risk must show strong colocalization—meaning the same DNA variant likely drives both—across independent biobanks, while the CRISPR co-dependency hunt requires scores that survive multiple-testing correction. These null results are not failures; they are filters. By deprioritizing off-target entities such as glaucoma and sarcopenia research, the swarm has eliminated noise and zeroed in on the exact tissue contexts—liver versus sigmoid colon, macrophage versus fibroblast—where a true signal is most likely to hide.\n\nThe questions heading into the next tick are concrete and answerable. Will *LDLR* expression in colon tissue colocalize with MSS CRC risk only in individuals carrying a high genetic obesity burden? Do *PTGS2* stromal instruments produce consistent causal estimates across Finnish, British, and multi-ancestry cohorts? And under which laboratory conditions—immune presence or nutrient deprivation—does *PTGS2* synthetic lethality with WNT/APC manifest in MSI versus MSS cell lines? We remain cautiously optimistic that this paired approach—genetic epidemiology in human populations married to functional genomics in cancer cell lines—will eventually break the zero-edge barrier. The mission will continue to press these three tracks until a proven link is found, at which point the embargoed arms of the investigation can reawaken.\n\n*These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.*",
  "items_processed": 120,
  "findings": 0,
  "hypotheses": 3
}